| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| 100mg | |||
| Other Sizes |
| Targets |
The primary target of BDC2.5 mimotope 1040-31 is the BDC2.5 T-cell receptor (TCR). It is a strong agonist that specifically binds to and activates this TCR. The BDC2.5 TCR is a well-characterized TCR from a diabetogenic T cell clone, making it a key model for studying type 1 diabetes. By binding to this TCR, the mimotope triggers downstream signaling pathways that lead to T-cell activation, proliferation, and cytokine production. This interaction is central to its use in studying the mechanisms of autoimmune diabetes.
|
|---|---|
| ln Vitro |
In vitro, BDC2.5 mimotope 1040-31 is a strong agonistic peptide for the diabetogenic T cell clone BDC2.5. It can stimulate BDC2.5 cells, with cells showing a good response to this mimotope. Its activity is assessed by its ability to activate BDC2.5 TCR Tg+ T cells in culture. This activation is typically measured by T-cell proliferation, cytokine production (e.g., IL-2, IFN-gamma), and upregulation of activation markers. It is a key tool for studying the specificity and function of this diabetogenic T-cell clone.
|
| ln Vivo |
In vivo, BDC2.5 mimotope 1040-31 is used in mouse models to study the pathogenesis of type 1 diabetes. By administering this mimotope, researchers can activate the BDC2.5 T cells in vivo, allowing them to study the progression of autoimmune diabetes. It can be used to track and study the diabetogenic T-cell response, providing insights into the mechanisms that lead to the destruction of insulin-producing beta cells. This model is crucial for testing immunotherapies and understanding the disease process.
|
| Enzyme Assay |
Cell-free receptor binding assays for BDC2.5 mimotope 1040-31 are not typically performed, as it is a peptide that activates a cellular receptor, the TCR. The interaction is typically studied in cellular assays. However, surface plasmon resonance (SPR) can be used to study the direct binding of the mimotope to the recombinant BDC2.5 TCR. The peptide is immobilized on a sensor chip, and the TCR is flowed over it. The binding affinity (Kd) is determined from the association and dissociation rates. This provides a direct measure of the mimotope's affinity for the TCR.
|
| Cell Assay |
For in vitro cellular experiments, BDC2.5 TCR Tg+ T cells are cultured in appropriate media. These cells are treated with BDC2.5 mimotope 1040-31 at various concentrations (typically 0.1-100 ug/mL). T-cell activation is assessed by measuring proliferation using [3H]-thymidine incorporation or CFSE dilution. Cytokine production (e.g., IL-2, IFN-gamma) in the supernatant is measured by ELISA. The upregulation of activation markers (e.g., CD25, CD69) is assessed by flow cytometry. These experiments define the potency and efficacy of the mimotope.
|
| Animal Protocol |
In vivo animal experiments with BDC2.5 mimotope 1040-31 are conducted in BDC2.5 TCR transgenic mice, which are a well-established model for studying type 1 diabetes. A common protocol involves injecting the mimotope subcutaneously or intraperitoneally at various doses (e.g., 10-100 ug per mouse). The effects on the immune system are assessed by monitoring T-cell activation, proliferation, and cytokine production in lymphoid organs. In some models, the progression of diabetes is monitored by measuring blood glucose levels and assessing insulitis (inflammation of the pancreatic islets).
|
| ADME/Pharmacokinetics |
BDC2.5 mimotope 1040-31 is a peptide with a molecular weight of 1348.61 g/mol and a molecular formula of C63H97N17O14S. Its sequence is YVRPLWVRME. As a peptide, it is administered by injection in experimental settings. It is stable as a powder and should be stored at -80degC for long-term storage or at -20degC for up to a year. It is soluble in aqueous buffers or DMSO. Its half-life in vivo is short due to proteolytic degradation.
|
| Toxicity/Toxicokinetics |
The toxicity profile of BDC2.5 mimotope 1040-31 is not extensively characterized, as it is used as a research tool in specific mouse models. At the doses used for T-cell stimulation, it is generally well-tolerated. However, as a strong agonist, it can induce a robust immune response, which could be pathological if not controlled. The compound is for research use only and not for human therapeutic use. It should be handled with standard laboratory precautions.
|
| References |
|
| Additional Infomation |
BDC2.5 mimotope 1040-31 is a synthetic peptide that mimics an antigenic determinant recognized by the BDC2.5 T-cell receptor. It is a strong agonist for the diabetogenic T cell clone BDC2.5. It is used as a research tool to study type 1 diabetes, specifically the autoimmune T-cell response that targets pancreatic beta cells. It is specific for BDC2.5 TCR Tg+ T cells and is a key reagent for studying the mechanisms of autoimmune diabetes.
|
| Molecular Formula |
C65H101N17O16S
|
|---|---|
| Molecular Weight |
1408.6667535305
|
| Exact Mass |
1347.712
|
| CAS # |
329696-49-3
|
| Related CAS # |
BDC2.5 mimotope 1040-31 TFA
|
| PubChem CID |
155977594
|
| Sequence |
YVRPLWVRME
|
| Appearance |
White to off-white solid powder
|
| LogP |
-1.4
|
| Hydrogen Bond Donor Count |
17
|
| Hydrogen Bond Acceptor Count |
18
|
| Rotatable Bond Count |
40
|
| Heavy Atom Count |
95
|
| Complexity |
2640
|
| Defined Atom Stereocenter Count |
10
|
| SMILES |
CC(C)C[C@@H](C(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(=O)O)C(=O)O)NC(=O)[C@@H]3CCCN3C(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC4=CC=C(C=C4)O)N
|
| InChi Key |
PSQOJBFNOHZXHH-RQXVNRIXSA-N
|
| InChi Code |
InChI=1S/C63H97N17O14S/c1-33(2)29-46(77-57(89)48-17-12-27-80(48)60(92)44(16-11-26-70-63(67)68)74-59(91)50(34(3)4)78-52(84)40(64)30-36-18-20-38(81)21-19-36)55(87)76-47(31-37-32-71-41-14-9-8-13-39(37)41)56(88)79-51(35(5)6)58(90)73-42(15-10-25-69-62(65)66)53(85)72-43(24-28-95-7)54(86)75-45(61(93)94)22-23-49(82)83/h8-9,13-14,18-21,32-35,40,42-48,50-51,71,81H,10-12,15-17,22-31,64H2,1-7H3,(H,72,85)(H,73,90)(H,74,91)(H,75,86)(H,76,87)(H,77,89)(H,78,84)(H,79,88)(H,82,83)(H,93,94)(H4,65,66,69)(H4,67,68,70)/t40-,42-,43-,44-,45-,46-,47-,48-,50-,51-/m0/s1
|
| Chemical Name |
(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-1-[(2S)-2-[[(2S)-2-[[(2S)-2-amino-3-(4-hydroxyphenyl)propanoyl]amino]-3-methylbutanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]pyrrolidine-2-carbonyl]amino]-4-methylpentanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-3-methylbutanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-4-methylsulfanylbutanoyl]amino]pentanedioic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture and light. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: ~16.7 mg/mL (~12.4 mM; with ultrasonication)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 1.67 mg/mL (1.24 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween-80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), Clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of DMSO stock solution (16.7 mg/mL) to 400 μL of PEG300 and mix well; then add 50 μL of Tween-80 and mix well; finally add 450 μL of physiological saline and adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 1.67 mg/mL (1.24 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), Clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of DMSO stock solution (16.7 mg/mL) to 900 μL of 20% SBE-β-CD saline and mix well. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 0.7099 mL | 3.5494 mL | 7.0989 mL | |
| 5 mM | 0.1420 mL | 0.7099 mL | 1.4198 mL | |
| 10 mM | 0.0710 mL | 0.3549 mL | 0.7099 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
